

DAFTAR PUSTAKA

- Adham, M., Antonius, N., Kurniawan, Muhtadi, A.I., Roezin, A., Hermani, B., Gondhowiardjo, S., Tan, B., Middeldorp, J.M., 2012. Nasopharyngeal in Indonesia: epidemiology, incidence, sign and symtomp at presentation. *Chin J Cancer*; 2012; Vol. 31 Issue 4.
- Ajit, K., and Seena, 2012. Review: Circulating microRNAs as Biomarkers, Therapeutic, Targets, and Signaling Molecules. *Sensors*. 12: 3359-3369.
- Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 116:281–297.
- Berger, A.H., Knudson, A.G., Pandolfi, P.P., 2011. A continuum model for tumour suppression. *Nature*. 476:163-9.
- Blower, P.E., Chung, J.H., Verducci, J.S., 2008. MicroRNAs modulate the chemosensitivity of tumor cells. *Mol Cancer Ther*. 7:1–9.
- Bourguignon, L.Y., Spevak, C.C., Wong, G., 2009. Hyaluronan-CD44 interaction with protein kinase c(epsilon) promotes oncogenic signaling by the stem cell marker nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein pcd4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. *J Biol Chem*. 284: 26533–46.
- Borel, F, Konstantinova, P., Jansen, P.L.M., 2012. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. *J Hepatology*. Vol. 56. 1371–1383.
- Calin, G.A., Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M., 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci .USA* 101: 2999-3004.
- Chao, X., Han, Y., He, L., 2011. Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment. *Oral Oncol*. 47:747-52.
- Chen, X., Zhang, J., Zen, K., Zhang, C.Y., 2011. *MicroRNA as Blood-based Biomark of Cancer*. Jiangsu Diabetes Center. Nanjing University, Nanjing, Jiangsu 210093, PR China.
- Chin, L.J., 2008. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. *Cancer Res*.68: 8535–8540.
- Choi, C., 2005. Review : ABC Transporters as Multidrug Resistance Mechanisms and the Development of Chemosensitizers for Their Reversal. *Canc. Cell. Int*. Pp. 1-13.
- Cortez, M.A., Carlos, B.R., Ferdin, J., Gabriel, L-B., Sood, A.K., and Calin, G.A., 2011. MicroRNAs in body fluids the mix of hormones and biomarkers. *Nat. Rev. Clin. Oncol*. 8: 467–477.
- Dou, H., Hu, D., Lam, C., Liu, Y., Wang, X., Zhang, W., 2014. Retrospective analysis of results of treatment for nasopharyngeal carcinoma in Macao. *Chin J Cancer Res*. 26(2):148-158.
- Dong, J. T., 2006. Prevalentmutationsinprostatecancer. *J Cell Biochem*. 97:433–47.
- Esquela, Kerscher, A., and Slack, F. J., 2006. Oncomirs microRNAs with a role in cancer. *Nat. Rev. Cancer* .6:259–269.

- Esteller, M., 2008. Epigenetics in cancer. *N. Engl. J. Med.* 358:1148–1159.
- Etzioni, R., 2003. The case for early detection. *Nat Rev Cancer* 3:243–252.
- Eulalio, A., Huntzinger, E., and Izaurralde, E., 2007. Getting to the Root of miRNA-Mediated Gene Silencing. *Cell.* 132. Elsevier Inc.
- Felice, F.D., Musio, D., Magnante, A.L., Bulzonetti, N., Francesco, I.D., Tombolini, V., 2014. Solitary rib metastasis of nasopharyngeal carcinoma. *Chin J Cancer Res.* 26(2):219-221.
- Ganepola, AP, Nizin, J, Rutledge, J.R, Chang, D.H, 2014. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. *World J Gastrointest Oncol.* 6(4): 83-97.
- Ha, T.Y., 2011. The role of microRNAs in regulatory T cells and in the immune response. *Immune Netw.* 11, 11–41.
- Hammad, S. A., and Zihlif, M., 2012, Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. *Genomics.* 101: 213–220.
- Hwang, P.H., Yi, H.K., Kim, D.S., Nam, S.Y., Kim, J.S. and Lee, D.Y., 2001. Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. *Cancer Lett.* 172, 83–91.
- Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., 2011. Global cancer statistics. *C.A. Cancer J. Clin.* 61: 69–90.
- Ji, J., Wang, X.W., 2009. New kids on the block: Diagnostic and prognostic microRNAs in hepatocellular carcinoma. *Cancer Biol Ther.* 8.
- Kementerian Kesehatan RI., 2015. PUSAT DATA DAN INFORMASI KEMENTERIAN KESEHATAN RI.
- Kim, J., Coffey, D.M., Creighton, C.J., Yu, Z., Hawkins, S.M., Matzuk, M.M., 2012. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. *Proc Natl Acad Sci USA.* 109:3921–6.
- Knobbe, C.B., Merlo, A., and Reifemberger, G., 2002. Pten signaling in gliomas. *Neuro-Oncology.*
- Kong, F., Ying, H., Chengrun Du, C., Huang, S., Zhou, J., Chen, J., Sun, L., Chen, X., and Hu, C., 2014. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma. *Rad Onco.* 9:60.
- Ladeiro, Y., Couchy, G., Balabaud, C., 2008. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. *Hepatology.* 47:1955–63.
- Lee, J. T., Steelman, L. S., McCubrey, J. A. 2005. Modulation of Raf/MEK/ERK Pathway in Prostate Cancer Drug Resistance. *Int J Oncol;* 26:1637–1645.
- Leitner, A. 2009. *MicroRNA Target Prediction.: Institute for Genomics and Bioinformatics.* Graz University of Technology.
- Li, Y.L., Tian, Z., Wu, D.Y., Fu, B.Y., Xin, Y., 2005. Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and pre cancerous lesions. *J Gastroenterol.* 11:285–8.
- Limtrakul, P., Chearwae, W., Shukla, S., Phisalpong, C., and Ambudkar, S. V., 2007. Modulation of Function of Three ABC Drug Transporters, P-glycoprotein (ABCB1), Mitoxantrone Resistance Protein (ABCG2) and Multidrug Resistance Protein 1 (ABCC1) by Tetrahydrocurcumin, a Major Metabolite of Curcumin. *Mol Cell Biochem.* 296: 85–95.

- Liang, Z., Wu, H., Xia, J., 2010. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. *Biochem Pharmacol.* 79:817–24.
- Lo, K.W., To, K.F., Huang, D.P., 2004. Focus on nasopharyngeal carcinoma. *Cancer Cell.* 5:423-428.
- Lotan, T.L., Gurel, B., Sutcliffe, S., 2011. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. *Clin. Cancer. Res.*17:6563-73.
- Lu, J., Getz, G., Miska, E.A., 2005. MicroRNA expression profiles classify human cancers. *Nature.* 435:834–8.
- Lytle, J.R., Yario, T.A., Steitz, J.A., 2007. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5'UTR as in the 3'UTR. *Proc Natl Acad Sci USA.* 104:9667–72.
- Ma, Y., Wang, X., and Jin, H., 2013. Methylated DNA and microRNA in Body Fluids as Biomarkers for Cancer Detection. *Int. J. Mol. Sci.* 14.
- Marcum, K.J., and Tishler, R.B., 2010. Head and neck carcinomas across the age spectrum: epidemiology, therapy, and late effects. *Semin Rad Oncol*, vol. 20, no. 1, pp.52–57.
- McLornan, D.P., McMullin, M.F., Johnston, D.B. and Longley, P., 2007. Molecular mechanisms of drug resistance in acute myeloid leukemia. *Expert Opin. Drug Metab. Toxicol.* 3:363–377.
- McCubrey, J. A , Steelmana, L. S., Abramsa, S. L., Leea, J. T., Changa, F., Bertranda, F. E., Navolanica, P. M., Terrianb, D. M., Franklina, R. A., D'Assorod, A., Salisburyd, J. L., Mazzarinoe, M. C., Stivalae, F., Libra, M., 2006. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT Pathways in Malignant Transformation and Drug Resistance. *Advan. Enzyme Regul.* 46 249–279.
- Mei, M., Ren, Y., Zhou, X., 2010. Down-regulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. *Technol Cancer Res Treat.* 9:77–86.
- Meng, F., Henson, R., Lang, M., 2006. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. *Gastrn.* 130:2113–29.
- Minami, A., Nakanishi, A., Ogura, Y., Kitagishi, Y., and Matsuda, S., 2014. Connection between tumor suppressor BRCA1 and PTEN in damaged DNA repair. *Mol and Cell Oncol.*Vol 4. 318.
- Muller, A., Homey, B., Soto, H., 2001. Involvement of chemokine receptors in breast cancer metastasis. *Nature* . 410: 50–56.
- Nana-Sinkam SP and Croce CM (2013). Clinical applications for microRNAs in cancer. *Clin Pharmacol Ther* . 93: 98–104.
- Noonan, E.J., Place, R F., Li, L.C., 2011. MicroRNAs in Predicting Radiotherapy and Chemotherapy Response. in Cho, C.S. William (Eds.). *MicroRNAs in Cancer Translational Research.* Springer: Pp. 415-448.
- Pelengaris, S. and Khan, M. 2006. *The Molecular Bio of Cancer.* Blackwell Pub. Pp 1-478.
- Pezzolesi, M.G., Platzer, P., Kristin, A. Waite, K.A., and Charis Eng, C., 2008. Differential Expression of PTEN-Targeting MicroRNAs miR-19a and miR-21 in Cowden Syndrome. *J Hum Genetic.* 82:1141–1149.

- Phin, S., Moore, M.W., and Cotter, P.D., 2013. Genomic rearrangements of PTEN in prostate cancer. *Fonc* 3:1-9.
- Place, A. E., Huh, S. J., and Polyak, K., 2011. The Microenvironment in Breast Cancer Progression: Biology and Implications for Treatment. *Breast Canc Res.* 13:227.
- Place, R.F., Li, L.C., Pookot, D., Noonan, E.J., and Dahiya, R., 2008. MicroRNA-373 induces expression of genes with complementary promoter sequences. *Proc. Natl Acad. Sci. USA* 105, 1608–1613.
- Plieskatt, J.L., Rinaldi, G., Feng, Y., Levine, P.H., Easley, S., Martinez, E., Hashmi, S., Sadeghi, N., Brindley, P.J., Bethony, J.M., Mulvenna, J.P., 2014. Methods and matrices: approaches to identifying miRNAs for Nasopharyngeal carcinoma. *J Transl Med* . 12:3.
- Rajewsky, N., 2006. microRNA target predictions in animals. *Nat Genet.*38 Suppl: S8-13.
- Rodriguez-Gonzalez, F.G., Sieuwerts, A.M., Smid, M., 2010. MicroRNA-34a suppresses invasion through down-regulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. *Breast Cancer Res Treat.* 31:1037–44.
- Saal, L.H., Gruvberger-Saal, S.K., Persson, C., Lovgren, K., Jumppanen, M., Staaf, J., Jonsson, G., Pires, M.M., Maurer, M., Holm, K., 2008. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. *Nat. Genet.* 40, 102–107.
- Saj, A., Lai, E.C., 2011. Control of microRNA biogenesis and transcription by cell signaling pathways. *Curr. Opin. Genetic Develop.* 21.
- Schwarzenbach, H., Nishida, N., Calin, G.A., Pantel, K., 2014. Clinical relevance of circulating cell-free microRNAs in cancer. *Nat. Rev. Clin. Oncol.*
- Salmena, L., Carracedo, A., Pandolfi, P.P., 2008. Tenets of PTEN Tumor Suppression. *Cell* 133. Elsevier Inc.
- Selcuklu, S.D., Donoghue, M.T., Spillane, C., 2009. MiR-21 as a key regulator of oncogenic processes. *Biochem Soc Trans.* 37:918–25.
- Shen, J., Todd, N.W., Zhang, Yu, H.L., Lingxiao, X., Mei, Y., Guarnera, M., Liao, J., Chou, A., Larry, C., Lu, Jiang, Z., Fang, H., Ruth L Katz,R.L., and Jiang, F., 2011. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. *USCAP.* 91:579–587.
- Shin, Y., Benjamin, E., Paluch, Wang, X., Jiang, X., 2012. PTEN at a glance. *J Cell Sci* . 125:4687–4692.
- Simpson, L. and Parsons, R., 2001. PTEN: life as a tumor suppressor. *Exp. Cell Res.* 264, 29–41.
- Song MS, Salmena L, Pandolfi, P.P., 2012. The functions and regulation of the PTEN tumour suppressor. *Nat Rev Mol Cell Biol.*13: 283-96.
- Suzuki, M.M., 2008. Bird, A. DNA methylation landscapes: Provocative insights from epigenomics. *Nat. Rev. Genet.* 9:465–476.
- Swanton, C., Szallasi, Z., Brenton, J. D., and Downward, J., 2008. Review : Functional Genomic Analysis of Drug Sensitivity Pathways to Guide Adjuvant Strategies in Breast Cancer. *Breast Canc Res.*10:214.
- Tsai, S., Lin, C., Wu, S., Hou, L. A., Ma, H., Tsai, L., and Hou, M., 2009. Side Effects After Docetaxel Treatment in Taiwanese Breast Cancer Patients With

- CYP3A4, CYP3A5, and ABCB1 Gene Polymorphisms. *Clin Chim Acta*. 404: 160–165.
- Tsujiura, M., Ichikawa, D., Komatsu, S., Shiozaki, A., Takeshita, H., T. Kosuga, T., Konishi, H., Morimura, R., Deguchi, K., Fujiwara, H., Okamoto, K., Otsuji, E., 2010. Circulating microRNAs in plasma of patients with gastric cancers. *J. Cancer*. 102:1174–1179.
- Ura, S., Honda, M., Yamashita, T., 2008. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. *Hepatology*. 49:1098–112.
- Vasilatou, D., Papageorgiou, S., Pappa, V., Papageorgiou, E., Dervenoulas, J., 2009. The role of microRNAs in normal and malignant hematopoiesis. *Euro J Haema*. 84:1–16.
- Vazquez, F., Grossman, S.R., Takahashi, Y., Rokas, M.V., Nakamura, N., and Sellers, W.R., 2001. Phosphorylation of the Pten tail acts as an inhibitory switch by preventing its recruitment into a protein complex. *J. Biol. Chem*. 276, 48627–48630.
- Voorhoeve, P.M., and Agami, R., 2007. Classifying microRNAs in cancer: the good, the bad and the ugly, *Biochim. Biophys Acta*. 1775.(2):274–282.
- Wang, F., Zheng, Z., Guo, J., 2010. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. *Gynecol Oncol*. 119:586–593.
- Wang, J.Y., Huang, T.J., Chen, F.M., Hsieh, M.C., Lin, S.R., Hou, M.F., 2003. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. *Virchows Arch*. 442:437–43.
- Wei, W.I., Sham, J.S., 2005. Nasopharyngeal carcinoma. *Lancet*. 365:2041–2054.
- Wei, J., Liu, L-K., Gao, W., Zhu, C-J., Liu, Y-L., Cheng, T., Shu, Y-Q., 2011. Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer. *Chin J Cancer Res*. 23(2): 123-128.
- Wind, N. S. and Holen, I., 2011. Review Article : Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies. *Int J Breast Canc*. 1-12.
- Wong, Q.W., Ching, A.K., Chan, A.W., 2010. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. *Clin Cancer Res*. 16: 867–75.
- World Health Organization, 2013. *Latest world cancer statistics. Global cancer burden rises to 14.1 million new cases in 2012*. World Health Organization, Geneva.
- Wu, Y., Dowbenko, D., Spencer, S., Laura, R., Lee, J., Gu, Q., and Lasky, L.A., 2000. Interaction of the tumor suppressor Pten/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. *J. Biol. Chem*. 275, 21477–21485.
- Xu, L-f., Wu, Z-p., Chen, Y., Zhu, Q-s., Hamidi, S., 2014. MicroRNA-21 Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by Targeting PTEN, RECK and Bcl-2 in Lung Squamous Carcinoma, Gejiu City, China.
- Xu, X., Yang, H., Huo, X., 2004. “Expression and significance of PTEN in nasopharyngeal carcinoma,” *J Clin Otorhino*. Vol. 18, no. 11, pp. 658–659.

- Yamamichi, N., Shimomura, R., Inada, K., Sakurai, K., Haraguchi, T., Ozaki, Y., Fujita, S., Mizutani, T., Furukawa, C., Fujishiro, M., Ichinose, M., Shiogama, K., Tsutsumi, Y., Omata, M., Iba, H., 2009. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. *Clin. Cancer Res.*15: 4009-4016.
- Yang, H., Kong, W., He, L., 2008 MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. *Cancer Res.* 68:425–33.
- Yi, J.L., Gao, L., Huan, X.D., 2006. Nasopharyngeal carcinoma treated by radical radiotherapy alone:ten year experience of a single institution. *Int J Radiat Oncol Biol Phys.*65(1):161-168.
- Yin, R., Qin, Y., Macara, I. G., and Cullen, B. R., 2003. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev.* 17, 3011–3016.
- Zeng, B.R., and Cullen, 2004. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. *Nucleic Acids Res.* 32.4776–4785.
- Zhang, L., Chen, Q.Y., Liu, H., Tang, L.Q., Mai, H.Q., 2013. Emerging treatment options for nasopharyngeal carcinoma. *Drug Des. Devel. Ther.* 7: 37–52.
- Zheng, Y., Yi, R and Cullen, B. R., 2003. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. *Proc.Natl Acad. Sci. USA.* 100, 9779–9784.
- Zhou, M., Liu, Z., Zhao, Y., 2010. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic bcl-2 antagonist killer 1 (BAK1). *J Biol Chem.* 285:21496–507.